Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors [Yahoo! Finance]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: Yahoo! Finance
Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million , bringing the total Series B / B-1 gross proceeds to $29.8 million . The offering provides the Company with significant working capital to execute its business plan as it approaches critical reimbursement milestones. The Company also announced that its Board of Directors has appointed healthcare industry veteran Dennis Matheis to serve as a Director, effective May 6, 2024 "
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.MarketBeat
- Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.MarketBeat
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial ResultsPR Newswire
- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall [Yahoo! Finance]Yahoo! Finance
LUCD
Sec Filings
- 5/14/24 - Form 8-K
- 5/13/24 - Form 10-Q
- 5/9/24 - Form 3
- LUCD's page on the SEC website